Quarterly ResultMay 5, 2026, 08:38 AM
Disc Medicine Q1 Net Loss $63.5M; $730M Cash; Bitopertin Phase 3 Enrolled
AI Summary
Disc Medicine reported a net loss of $63.5 million for the first quarter ended March 31, 2026, an increase from $34.1 million in the prior year. Despite the increased loss due to higher operating costs, the company maintains a strong financial position with $730.2 million in cash, cash equivalents, and marketable securities, providing a runway into 2029. The company also announced significant progress in its clinical pipeline, including the completion of enrollment for the Phase 3 APOLLO study of bitopertin and upcoming data presentations for DISC-0974 and DISC-3405.
Key Highlights
- Cash, cash equivalents, and marketable securities were $730.2 million as of March 31, 2026, providing runway into 2029.
- Net loss for Q1 2026 was $63.5 million, compared to $34.1 million for Q1 2025.
- Research and Development expenses increased to $45.9 million in Q1 2026 from $27.8 million in Q1 2025.
- Selling, General and Administrative expenses rose to $23.6 million in Q1 2026 from $12.2 million in Q1 2025.
- Phase 3 APOLLO study of bitopertin in EPP completed enrollment with 183 patients; topline data expected Q4 2026.
- Updated Phase 2 data for DISC-0974 in MF anemia (N=61 patients) to be shared at ASCO in June.
- Initial data from Phase 2 DISC-3405 in PV and Phase 1b DISC-3405 in SCD expected Q4 2026.
Price Impact
More from IRON